January was another impressive month of funding for the LSI Alumni, raising over $500 million in new capital across 12 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves.
Companies featured in the January 2025 update include:
Announced the initial close of its Series A funding round led by Varana Capital to support its next phase of growth. The company develops the SuperBall Meniscal Repair System, a knotless, all-suture, all-inside device designed to replicate inside-out tensioning of the meniscus.
Secured $115M in a Series B funding round, led by Dimension, to further develop its bioprinted tissue therapeutics platform. The funds will be used to accelerate the clinical development of various regenerative medicine solutions.
Closed a $120M equity financing round to drive commercial growth. The funds will enable the company to increase access to its four-day wearable insulin delivery devices for individuals with diabetes.
Secured an investment from CDP Venture Capital as part of the PNRR (Piano Nazionale di Ripresa e Resilienza) and the Next Generation EU initiative. The company is advancing CardioKit, an ultrasound imaging device designed for non-invasive treatment of cardiac arrhythmias.
Raised $80M in an oversubscribed Series C round to further develop its water vapor ablation therapy for kidney, prostate, and bladder cancer. The company will utilize the funds to support ongoing clinical trials and commercial scaling efforts.
Secured $37M in a Series D round to broaden access to GammaTile for patients with operable brain tumors in the United States. The investment will also support ongoing clinical evidence development and commercial growth.
Secured Series B funding and shared that 25 centers in the United States now offer the iotaSOFT Insertion System. iotaSOFT is designed to provide slow, controlled insertion of cochlear implant electrode arrays.
Secured $5M in funding from the DoD and NIH to further develop its Injectrode neuromodulation technology. The DoD grant will fund a randomized controlled trial for neurogenic bladder treatment after spinal cord injury, while NIH funding will support preclinical research on overactive bladder treatment.
Received a $35M venture loan facility from Horizon Technology Finance. The company plans to use the proceeds of the loan to expedite manufacturing and commercialization of its NanoCept, an antibacterial coating technology for orthopedic implants.
Completed a $50M Series A funding round led by Asabys and Buenavista. These funds will be used to expand Quibim’s product pipeline and AI models and support its commercial growth efforts.
Secured $28M to further develop its microrobotic solutions for neurosurgery. The funding will aid ongoing development, support preparations for human trials in 2026, and help establish U.S. operations in anticipation of FDA approval and market entry.
Raised $31M in a Series B funding round led by MindWorks Global (MWG). This funding will allow Zeto to grow its commercial and operational teams, accelerate growth, and enhance its ongoing research and development initiatives.
Stay tuned for more updates as these medical technology companies continue to innovate and lead the way in the medtech industry. As we look forward to LSI USA '25 in Dana Point next March, these achievements remind us of the incredible progress being made in the medtech sector.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy